|Bid||0.00 x 800|
|Ask||0.00 x 800|
|Day's Range||177.59 - 180.99|
|52 Week Range||136.50 - 194.92|
|Beta (3Y Monthly)||1.84|
|PE Ratio (TTM)||110.14|
|Earnings Date||Oct 23, 2018 - Oct 29, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||198.27|
Today I want to tell you about three stocks, each in its own emerging trend, that have huge upside potential in the transformative years ahead. Gene editing is just what it sounds like. CRISPR Therapeutics (NASDAQ:CRSP) is one of the three leaders in the gene editing sector.
CRISPR and Vertex were preparing to test the the ability of a new gene-editing technology, CRISPR/Cas9, in cutting out and replacing disease-causing snippets of DNA when the FDA placed the hold in May.
Vertex Pharmaceuticals (VRTX) is focused on developing and bringing to market therapies that treat cystic fibrosis. Vertex Pharmaceuticals has key collaboration agreements with CRISPR Therapeutics (CRSP) to develop treatments for underlying genetic causes of human diseases by using CRISPR-Cas9 technology. It also uses Moderna Therapeutics to develop mRNA (messenger ribonucleic acid) therapeutics for cystic fibrosis, BioAxone to evaluate VX-210 as a treatment for spinal cord injuries, and Parion Sciences to develop epithelial sodium channel inhibitors to treat pulmonary diseases.
How Is Vertex Pharmaceuticals Positioned in October? Vertex Pharmaceuticals’ (VRTX) cost of sales was $104.38 million in the second quarter of 2018 compared to $71.2 million in the second quarter of 2017. It incurred selling, general, and administrative expenses of $137.3 million in the second quarter of 2018 compared to $127.25 million in the second quarter of 2017.
In October, there are 24 analysts covering Vertex Pharmaceuticals (VRTX) stock. Twenty of them have given the stock a “buy” or higher rating, and four have given it a “hold.” The mean rating for the stock is 1.83 with a target price of $198.27, implying an upside potential of 12.9% over Vertex Pharmaceuticals’ closing price of $175.66 on October 11.
The Food and Drug Administration (FDA) has cleared the way for CRISPR Therapeutics Ltd. ( CRSP) and Vertex Pharmaceuticals Inc. ( VRTX) to start testing their genetically engineered treatment for sickle cell disease on U.S. patients. In a press release, the two companies said the FDA has now lifted its clinical hold, enabling them to begin trailing the experimental therapy. At the time, CRISPR and Vertex claimed that CTX001 was placed on hold because the FDA had additional questions as part of its review of the paperwork that companies submit for permission to start a clinical trial.
Check out the companies making headlines after the bell: Square SQ stock tumbled 8 percent in after-hours trading following news that CFO Sarah Friar is stepping down . Friar will stay at the company until December before departing to become CEO of Nextdoor, a localized social network for neighborhoods.
The FDA has lifted its hold on a highly anticipated gene-editing trial by CRISPR Therapeutics and Vertex Pharmaceuticals, allowing for the first company-backed trial in the U.S. to start by the end of the year.
Shares of Crispr Therapeutics AG rose more than 8% in the extended session Wednesday after the company and Vortex Pharmaceuticals Inc. said the Food and Drug Administration has lifted a clinical hold and has accepted a new-drug application for their gene-editing treatment for sickle-cell disease. Shares of Vortex rose 0.6% after ending the regular trading day down 5%. Crispr shares closed 0.6% lower.
In addition to the acceptance of the IND announced today, CRISPR and Vertex previously announced that they had obtained approvals of Clinical Trial Applications for CTX001 in multiple countries outside the U.S. for both β-thalassemia and SCD. The companies remain on track to initiate a Phase 1/2 clinical study in SCD by the end of 2018 and are currently enrolling patients with transfusion dependent β-thalassemia in a Phase 1/2 trial in β-thalassemia in Europe. The elevation of HbF by CTX001 has the potential to alleviate transfusion-requirements for β-thalassemia patients and painful and debilitating sickle crises for sickle cell patients.
Vertex (VRTX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
These three biotechs will soon present clinical trial results that could send their share prices screaming in one direction or the other.
Neurocrine Biosciences (NBIX) develops and commercializes therapies for neurology and endocrine disorders. Neurocrine Biosciences’ Ingrezza became the first FDA-approved drug to be approved for the treatment of individuals with tardive dyskinesia. Neurocrine Biosciences’ Ingrezza competes with Teva Pharmaceutical’s (TEVA) Austedo in the tardive dyskinesia drugs market.
For the past nearly 10 years, the Federal Reserve and all the central banks in all the industrialized nations have been managing interest rates to keep them outrageously low until the financial system had a chance to right itself. Royal Dutch Shell (NYSE:RDS.A, NYSE:RDS.B) is one of the biggest players in the global energy markets.
Ionis Pharmaceuticals (IONS), a leading biopharmaceutical company, has developed a variety of drugs for the treatment of life-threatening diseases through its broadly applicable drug discovery platform. Ionis reported earnings per share of -$0.29 on revenues of $117.7 million during the second quarter, reporting year-over-year growth of 5.0% during the quarter. The chart below compares the company’s revenues since the first quarter of 2017.
Vertex Pharmaceuticals (Europe) Limited today announced it has entered into an innovative access contract with the Danish pharmaceutical and procurement organization, Amgros. Effective from today, this first-of-its-kind contract includes current and future CFTR modulator medicines, and means eligible Danish cystic fibrosis (CF) patients will have access to all current medicines as well as future medicines after regulatory approval.
In the first half of this year, Vertex Pharmaceuticals’ (VRTX) revenue grew ~40% YoY (year-over-year) to $1.4 billion from $994.6 million. Kalydeco, Orkambi, and Symdeko saw revenue of $253.0 million, $311.0 million, and $186.0 million, respectively, in Q2 2018, compared with $250.0 million, $354.0 million, and $34.0 million, respectively, in Q1 2018. Vertex’s revenue growth could boost the First Trust NYSE Arca Biotechnology Index ETF (FBT), of which Vertex comprises ~3.33%.
Vertex Pharmaceuticals (VRTX) develops medicines for life-threatening diseases and is presently focused on developing drugs for cystic fibrosis and sickle-cell disease, partnering with CRISPR Therapeutics (CRSP) for the latter. Vertex’s Orkambi, Kalydeco, and Symdeko are top drugs in the cystic fibrosis market. Vertex stock’s 52-week low is $136.50, which it reached on December 7, 2017.
Stocks gave up all their gains and closed well in the red Wednesday, after the Federal Reserve hiked interest rates by a quarter-point, as widely expected.
In stock news today, strong showings from biotech stocks Alexion and Incyte lifted the Nasdaq 100 to a gain of nearly 1% in afternoon trading.